Lise Tarnow

Papers

1

Total Citations

4

H-Index

1

About

Lise Tarnow is a clinical researcher specializing in gastroenterology and neurogastroenterology, with a particular focus on gastroparesis—a chronic disorder characterized by delayed gastric emptying. Her work centers on evaluating novel therapeutic interventions, especially ghrelin receptor agonists, to alleviate the debilitating symptoms of this condition. Tarnow’s most cited study, a Phase 2 trial of the ghrelin agonist TZP-102, demonstrated that improvements in core gastroparesis symptoms—nausea, early satiety, bloating, and abdominal pain—correlated significantly with patients’ own ratings of overall treatment effect. This patient-centered outcome approach was pivotal in validating symptom-based endpoints for clinical trials in functional gastrointestinal disorders. Though her citation count is modest, Tarnow’s contribution is notable for bridging subjective patient experience with objective efficacy measures, a critical step in developing therapies for conditions where traditional biomarkers are lacking. Her work has informed subsequent research on ghrelin-based treatments and underscores the importance of aligning clinical trial design with patient priorities.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
TZP-102, Ghrelin Agonist Phase 2 Data: The Improvement in Symptoms of Gastroparesis (Nausea, Early Satiety, Bloating and Abdominal Pain) Significantly Correlated With Patient Rating of Overall Treatment Effect
4 citations · 2011
📈 Most Prolific Year: 2011 (1 Papers)
🤝 Key Collaborators: 12

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago